EcoR1 Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

EcoR1 Capital’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$5.45M	–	78
2021 Q2	$5.45M	Hold	100,000	–	–	0.2%	41
2021 Q1	$7.48M	Hold	100,000	–	–	0.33%	36
2020 Q4	$10.8M	Buy	+100,000	New	+$9.13M	0.58%	27
2019 Q3	–	Sell	-24,848	Closed	-$2.3M	–	44
2019 Q2	$2.3M	Buy	+24,848	New	+$1.73M	0.23%	36
2017 Q4	–	Sell	-10,400	Closed	-$1.53M	–	45
2017 Q3	$1.53M	Buy	+10,400	New	+$1.96M	0.2%	35
2017 Q2	–	Sell	-6,360	Closed	-$1.01M	–	41
2017 Q1	$1.01M	Hold	6,360	–	–	0.26%	26
2016 Q4	$773K	Hold	6,360	–	–	0.25%	27
2016 Q3	$882K	Buy	+6,360	New	+$807K	0.27%	30

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EcoR1 Capital's SYRS Position: Q3 2021 in Review

EcoR1 Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2021, closing a stake of 100,000 shares — an estimated $5.45M sold.

EcoR1 Capital first reported a position in SYRS in Q3 2016 and held it in 8 quarters. The position peaked at $10.8M in Q4 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q3 2021.

EcoR1 Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
EcoR1 Capital sold 100,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $5.45M.
EcoR1 Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 8 quarters.
EcoR1 Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $10.8M in Q4 2020.
100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on EcoR1 Capital's 13F filing for Q3 2021, filed 15 Nov 2021.